Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BSC-3201
- Development stage
- Preclinical
- Lead developer
- BiSiChem
- Modality
- Small Molecules
01
Overview
BSC-3201 is a small molecule drug that acts as an agonist of NR4A2 (nuclear receptor subfamily 4 group A member 2), also known as Nurr1. It is being developed primarily for the treatment of Parkinson's disease and potentially other nervous system and metabolic disorders. The drug was initially developed by BiSiChem and is currently in preclinical development, with Lifex Biolabs also listed as an active organization involved in its research. Its mechanism involves activating NR4A2, a nuclear receptor implicated in dopaminergic neuron function and survival, which may be beneficial for neurodegenerative diseases such as Parkinson's disease[1].
02
Targets
NR4A2 (Nuclear receptor subfamily 4 group A member 2)
Beyond the preview
Go deeper on BSC-3201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BSC-3201.